相关实验视频

Updated: Sep 9, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

伊米普拉通过Src无活化和卡斯巴酶依赖性亡来抑制骨肉瘤的侵袭

Yu-Chang Liu^1,2, Chi-Jung Fang³, Li-Cho Hsu⁴

¹Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, ROC.

Journal of cellular and molecular medicine

|September 1, 2025

概括

艾米普拉是一种抗抑郁药,通过诱导癌细胞死亡和抑制侵袭,有效地对抗骨髓瘤. 这项研究表明,伊米普拉在体内可降低瘤生长,而不会引起显著的毒性,这突显了它对OS的治疗潜力.

科学领域:

癌症学
药理学
分子生物学

背景情况:

骨肉瘤 (OS) 是一种具有高转移潜力的侵袭性骨癌,患者的治疗结果不佳.
三环抗抑郁药物伊米普拉已经显示出潜在的抗癌特性,需要进一步研究.
对于开发新的治疗策略来说,了解imipramine抗OS作用的机制至关重要.

研究的目的:

评估伊米普拉对骨髓瘤细胞的细胞毒性,促细胞衰竭和抗侵袭作用.
阐明伊米普拉对OS的作用的基础分子机制.
在临床前骨肉瘤模型中评估伊米普拉的疗效和安全性.

主要方法:

在体外研究中使用MTT和殖民地形成试验来评估细胞活力和伊米普拉的细胞毒性作用.
通过测量酶激活和与亡相关的蛋白质 (例如BAX,BCL-2,MCL-1,XIAP) 的表达来分析亡.
通过生物化学和组织病理学分析评估瘤生长,体重和全身毒性,使用U-2 OS异种移植小鼠模型评估体内疗效.

主要成果:

伊米普拉显著降低了骨髓瘤细胞活力和增殖,这种作用取决于剂量和时间.
该药物通过酶依赖的外部和内在途径诱导亡,调节关键的亡蛋白.
通过抑制Src酸化和降低表皮介质过渡 (EMT) 标志物,伊米普拉抑制了细胞迁移和侵入.
在体内,伊米普拉显著抑制了异种移植模型中的瘤生长,而不会对体重或重要器官功能产生不良影响.

结论:

伊米普拉通过Src信号增强亡并抑制侵袭,显示出强大的抗骨肉瘤活性.
这种药物在体内有效地降低了瘤的进展,并具有良好的安全性.
伊米普拉作为治疗骨肉瘤的潜在治疗药物具有前景.

关键词:

美国细胞亡这种药物一个入侵骨质肉瘤

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...